Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Open accessPublished version of a preprint
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; 2 of the 7 sources its claims cite were checked for support.
Abstract
A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, VOC 202012/01 (lineage B.1.1.7), emerged in southeast England in September 2020 and is rapidly spreading toward fixation. Using a variety of statistical and dynamic modeling approaches, we estimate that this variant has a 43 to 90% (range of 95% credible intervals, 38 to 130%) higher reproduction number than preexisting variants. A fitted two-strain dynamic transmission model shows that VOC 202012/01 will lead to large resurgences of COVID-19 cases. Without stringent control measures, including limited closure of educational institutions and a greatly accelerated vaccine rollout, COVID-19 hospitalizations and deaths across England in the first 6 months of 2021 were projected to exceed those in 2020. VOC 202012/01 has spread globally and exhibits a similar transmission increase (59 to 74%) in Denmark, Switzerland, and the United States.
Overview
CoChat Summary
TL;DR
Using sequencing, mobility/contact data, and dynamic transmission models, the paper finds that SARS-CoV-2 lineage B.1.1.7 (VOC 202012/01) spread substantially faster than prior lineages in England. The authors estimate it is 43 to 90% more transmissible, with no clear evidence of increased disease severity, but warn that faster spread would increase cases, hospitalizations, and the need for stronger control measures and faster vaccination.
Key findings
- In UK sequencing data, VOC 202012/01 had the highest relative population growth rate among 307 other lineages in the first 31 days after initial phylogenetic observation, and it continued to expand.
- A multinomial spline model estimated an increased growth rate of +0.104 day–1 relative to B.1.177, corresponding to a 77% increase in reproduction number R (95% CI, 73 to 81%) assuming a 5.5-day generation interval.
- Alternative analyses estimated R for VOC 202012/01 to be 43% higher (95% CI, 38 to 48%) from case-based regression, and 55% higher in Denmark, 74% higher in Switzerland, and 59% higher in the United States.
- The transmission model found no clear increase or decrease in severity, with odds ratios of 0.92 for hospitalization, 0.90 for critical illness, and 0.90 for death, but estimated transmissibility was 65% higher in the three most affected NHS regions and 82% higher across all seven regions.
Methods
- The study combined publicly available sequencing data from COG-UK, Pillar 2 testing data for S gene target failure, mobility data from Google Community Mobility, and social contact data from the CoMix survey, plus analogous sequence/RT-PCR data from Denmark, Switzerland, and the US.
- The authors used multinomial and binomial generalized linear mixed models, negative binomial state-space models, and an age- and region-structured deterministic compartmental transmission model fitted to multiple regional data streams, including deaths, hospital admissions, bed occupancy, PCR prevalence, seroprevalence, and VOC frequency.
- They compared five mechanistic hypotheses for the rapid spread, assessed model fit with deviance information criteria and short-term prediction, and ran scenario projections under varying NPIs and vaccination rollout rates.
Limitations
- The paper states that only a small number of intervention and vaccination scenarios were considered, and these should not be viewed as the only policy options.
- It states that the transmission model does not explicitly capture nursing home or hospital transmission, and regions were fit separately rather than jointly modeling between-region transmission.
- It notes uncertainty in model choice and parameter assumptions, including school-closure assumptions and NPI efficacy; these are limitations stated in the paper.
- Evident from the text: the severity analysis is based on early population-level data up to 24 December 2020, so delays from infection to hospitalization or death could obscure severity effects.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 2 Measuring the growth rate of VOC 202012/01. (A) Average relativized growth rate (i.e., a measure of variant fitness relative to other variants present during the 31 days after initial phylogenetic observation of a given variant) for all lineages in the COG-UK dataset, highlighting many lineages that have risen to prominence including B.1.177, the lineage with the highest relative abundance during the initial phylogenetic observation of VOC 202012/01. The shaded regions show conservative 95% rejection intervals; VOC 202012/01 is the first strain to exceed this threshold of faster relativized growth. Although many lineages exhibit above-average rates of growth, VOC 202012/01 has had the highest average relativized growth of any lineage in the history of COG-UK surveillance of SARS-COV-2. (B) Plotting all lineages’ relativized growth rates [ρ(t)] as a function of lineage age with conservative 95% rejection intervals highlights the significantly faster growth of VOC 202012/01 relative to other lineages at comparable times since their initial observation. Later declines in VOC and B.1.177 correspond to highly uncertain estimates of growth rates for data that are yet to be backfilled, so these declines in ρ(t) are sensitive to the processing of future sequences from recent dates (fig. S1). (C) Muller plots of the relative abundances of the major SARS-CoV-2 variants in the UK, based on a multinomial spline fit to COG-UK sequence data (Table 1 and table S1, separate-slopes multinomial spline model). A model extrapolation until 1 March 2021 is shown (shaded area). Minority variants are 440 circulating SARS-CoV-2 variants of low abundance. Specific colors represent the same lineages in (A) to (C). (D) Mean reproduction number over 7-day periods in 149 upper-tier local authorities of England (colored by the NHS England region they are within) plotted against the weekly proportion of Pillar 2 community SARS-CoV-2 tests with S gene target failure shows the spread of VOC 202012/01, a corresponding increase in the reproduction number in each local authority, and the eventual impact of targeted government restrictions from 20 December 2020. Testing data are shown for the week after the reproduction number estimates to account for delays from infection to test.](https://figures.cochat.ai/paper-figures/6a959b32b94b41a4aab77f4b47b25a40/estimated-transmissibility-and-impact-of-sars-cov-2-lineage-b-1-1-7-in-england-figure-2.jpg)
![Fig. 3 Comparison of possible biological mechanisms underlying the rapid spread of VOC 202012/01. Each row shows a different assumed mechanism. (A) Relative frequency of VOC 202012/01 (black line and ribbon respectively denote observed S gene target failure frequency with 95% binomial credible interval; purple line and ribbon respectively denote mean and 95% credible interval from model fit). (B) Posterior estimates (mean and 95% credible intervals) for relative odds of hospitalization (severe illness), relative odds of ICU admission (critical illness), relative odds of death (fatal illness), growth rate as a multiplicative factor per week [i.e., exp(7·∆r)], and the parameter that defines the hypothesized mechanism; all parameters are relative to those estimated for preexisting variants. (C to E) Illustrative model fits for the South East NHS England region: (C) fitted two-strain increased transmissibility model with VOC 202012/01 included; (D) fitted two-strain increased transmissibility model with VOC 202012/01 removed; (E) fitted single-strain model without emergence of VOC 202012/01. Black lines denote observed data; error bars denote the date range and 95% credible intervals for observed PCR prevalence and seroprevalence; colored lines and ribbons denote median and 95% credible intervals from model fit.](https://figures.cochat.ai/paper-figures/806d848e45ca40c19e0cc853e2b24dfc/estimated-transmissibility-and-impact-of-sars-cov-2-lineage-b-1-1-7-in-england-figure-3.jpg)

Verification
Claims the paper makes
2 Valid · 0 Not valid · 4 Not checked · 37 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“we did not find substantial differences in social interactions between regions of high and low VOC 202012/01 prevalence, as measured by Google mobility (11) and social contact survey data (12) from September to December 2020 (Fig. 1, E and F).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Characteristics of the new variant
What the sources say
- Not matchedcites [11]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [12] sourceExperimental — accuracy not yet measured
The Methods (Survey methodology) identify this as the CoMix social-contact survey, supporting the citation’s identification of the survey. But the Results (Participant characteristics) say the data reported here were collected on 24–27 March 2020; this paper does not establish that its reported data cover September–December 2020. The comparison between regions is presented as the citing authors’ own finding, not a finding attributed to this source. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This yielded an estimated increase in R for VOC 202012/01 of 43% (95% CI, 38 to 48%), increasing to a 57% (95% CI, 52 to 62%) increase if the spline was not included (Table 1, models 4a and 4b).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Measuring the new variant’s growth rate
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite these limitations, we found strong evidence that VOC 202012/01 is spreading substantially faster than preexisting SARS-CoV-2 variants.”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Discussion Combining multiple behavioral and epidemiological data sources with statistical and dynamic modeling, we estimated that the SARS-CoV-2 variant VOC 202012/01 has a 43 to 90% (range of 95% CrIs, 38 to 130%) higher reproduction number than preexisting variants of SARS-CoV-2 in England, assuming no changes to the generation interval. On the basis of early population-level data, we were unable to identify whether the new variant is associated with higher disease severity. Theoretical considerations suggest that, in some cases, natural selection may favor reduced severity of disease in pathogens (23). For this to be true, however, the pathogen’s infectious period must be truncated by disabling symptoms or death often enough that a less-virulent mutant generates more secondary infections despite potentially being less transmissible per contact, to the extent that decreased virulence and decreased transmissibility are consequences of the same mutation (e.g., one that decreases viral load). It is far from clear that this condition holds for SARS-CoV-2, given substantial transmission before the onset of severe symptoms. Regardless, without strengthened controls, there is a clear risk that future epidemic waves may be larger—and hence associated with greater burden—than previous waves. The UK government initiated a third national lockdown on 5 January 2021 in response to the rapid spread of VOC 202012/01, including school closures. Educational settings are among the largest institutions linked to SARS-CoV-2 clusters that remained open during the November 2020 lockdown (24), which means that the enacted school and university closures may have substantially assisted in reducing the burden of COVID-19 in early 2021. The increase in transmission associated with VOC 202012/01 has crucial implications for vaccination. First, it means that prompt and efficient vaccine delivery and distribution are even more important to reduce the impact of the pandemic in the near future. Increased transmission resulting from VOC 202012/01 will raise the herd immunity threshold, so that the potential burden of SARS-CoV-2 is larger and higher vaccine coverage will be required to achieve herd immunity. It is therefore extremely concerning that VOC 202012/01 has spread to at least 114 countries globally (2). Although VOC 202012/01 was first identified in England, a rapidly spreading variant has also been detected in South Africa (25, 26), where there was a marked increase in transmission in late 2020. Another variant exhibiting immune escape has emerged in Brazil (27, 28). Thus, vaccination timelines will also be a crucial determinant of future burden in other countries where similar new variants are present. Second, there is a need to assess how VOC 202012/01 and other emerging lineages affect the efficacy of vaccines (29, 30). Vaccine developers may need to consider developing formulations with variant sequences, and they may want to initiate post-licensure studies to detect differences in efficacy between the preexisting and new variants. Licensing authorities may need to clarify abbreviated pathways to marketing for vaccines that involve altering strain formulation without any other changes to their composition. There are limitations to our analysis. We have considered a small number of intervention and vaccination scenarios, which should not be regarded as the only available options for policy-makers. Our transmission model does not explicitly capture nursing home or hospital transmission of SARS-CoV-2, and we fit the model to each region of England separately rather than pooling information across regions and explicitly modeling transmission between regions. There are also uncertainties in the choice of model used to generate these predictions, and the exact choice will yield differences in the measures needed to control the epidemic. We note that even without increased susceptibility of children to VOC 202012/01, the more efficient spread of the variant implies that the difficult societal decision of closing schools will be a key public health question for multiple countries in the months ahead. We only assess relative support in the data for the mechanistic hypotheses proposed, but there may be other plausible mechanisms driving the resurgence of cases that we did not consider, and we have not identified the specific combination of mechanisms driving the increased transmission of VOC 202012/01. We identify increased transmissibility as the most parsimonious mechanistic explanation for the higher growth rate of VOC 202012/01, but a longer infectious period also fits the data well (table S4) and is supported by longitudinal testing data (17). Our conclusions about school closures were based on the assumption that children had reduced susceptibility and infectiousness relative to adults (19), but the precise values of these parameters and the impact of school closures remain the subject of scientific debate (31). We based our assumptions about the efficacy of NPIs on the measured impact on mobility of previous national lockdowns in England, but the impact of policy options cannot be predicted with certainty. Despite these limitations, we found strong evidence that VOC 202012/01 is spreading substantially faster than preexisting SARS-CoV-2 variants. Our modeling analysis suggests that this difference could be explained by an overall higher infectiousness of VOC 202012/01, but not by a shorter generation time or immune escape alone. Further experimental work will provide insight into the biological mechanisms for our observations, but given our projections of a rapid rise in incidence from VOC 202012/01—and the detection of other novel and highly transmissible variants (25–28)—there is an urgent need to consider what new approaches may be required to sufficiently reduce the ongoing transmission of SARS-CoV-2.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we found that the relative population growth rate of VOC 202012/01 in the first 31 days after its initial phylogenetic observation was higher than that of all 307 other lineages with enough observations to obtain reliable growth-rate estimates (Fig. 2A and fig. S1).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Measuring the new variant’s growth rate
plainn = 150,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportion of COVID-19 cases attributable to VOC 202012/01 increased rapidly in all regions of England, following an initial expansion in the southeast (Fig. 1A)”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Characteristics of the new variant
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
18 more claims
Create a free account to see all 43 claims and every source verdict.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“B.1.1.7 to be between 43% and 82%3 more transmissible than preexisting variants in the United Kingdom.”
From New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently, viral variants of concern have emerged in the UK (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) that harbor specific mutations in their S proteins that may be associated with increased transmissibility (50–55).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several emerging viral variants of concern have been identified that have mutations in the spike protein, including the B.1.1.7 variant (originating from the UK and which has eight spike mutations92), the B.1.351 variant (originating from South Africa) and the P.1 variant (originating from Brazil and which also contains multiple mutations in the spike protein and is spreading widely)57,93.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“Epidemiological studies suggest that it was approximately 50% more transmissible than previously circulating UK variants 191,197,198 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [198]
The cited source says what the claim attributes to it.
In the citing paper
“it has been previously reported that B.1.1.7 is associated with lower Ct values, corresponding to higher VLs 3”
From Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals (2021) · cites this paper as [3]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
Markov Processes: Characterization and Convergence
Ethier, S. N., & Kurtz, T. G. (1986) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316658 · Cited by 3,634
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
Advanced Bayesian Multilevel Modeling with the R Package brms
Bürkner, P.-C. (2018) · The R Journal · doi:10.32614/rj-2018-017 · Cited by 3,015 · cited 9×
“168) 67 (53-83) 120 (92-152) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE North West VOC vs.”
BackgroundMethodInfluentialSocial Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases
Mossong, J., Hens, N., Jit, M., Beutels, P., Auranen, K., Mikolajczyk, R., Massari, M., Salmaso, S., Tomba, G. S., Wallinga, J., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050074 · Cited by 2,900 · cited 10×
“105) 43 (40-46) 72 (67-78) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London VOC vs.”
BackgroundInfluentialSelf-citationProjecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H., & Lipsitch, M. (2020) · Science · doi:10.1126/science.abb5793 · Cited by 2,611 · cited 8×
“068) 23 (18-28) 37 (29-46) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London B.”
BackgroundResultInfluentialEstimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
Self-citationA dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · cited 10×
“068) 23 (18-28) 37 (29-46) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London B.”
BackgroundInfluential
Cited by
Items 601–700 of 2,327
Tödt, D., Meister, T. L., Tamele, B., Howes, J., Paulmann, D., Becker, B., Brill, F. H. H., Wind, M., Schijven, J. F., Heinen, N., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102908 · Cited by 32
Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion
Li, C.-J., Chao, T., Chang, T.-Y., Hsiao, C.-C., Lu, D.-C., Chiang, Y.-W., Lai, G.-C., Tsai, Y., Fang, J., Ieong, S., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01814-21 · Cited by 32
Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine
Coléon, S., Wiedemann, A., Surénaud, M., Lacabaratz, C., Hüe, S., Prague, M., Cervantes-Gonzalez, M., Wang, Z., Ellis, J., Sansoni, A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104062 · Cited by 29
“…Gamma, 14 B.1.617.2 Delta, 15 and recently emerged B.1.1.529 Omicron variants 16 exhibit several specific or shared mutations within the S sequences, raising substantial new concerns due to their increased transmissibility 17 and ability to escape convalescent and vaccine-induced antibody responses.”
InfluentialGenomic evidence for divergent co-infections of co-circulating SARS-CoV-2 lineages
Zhou, H., Cheng, Y., Xu, L., Li, J.-Y., Tao, C.-Y., Ji, C., Han, N., Yang, R., Wu, H. M., Li, Y., et al. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.07.042 · Cited by 39
“Among them, Alpha variant (B.1.1.7 and descendent lineages) was estimated to have greater than 50 % enhanced transmissibility [4].”
InfluentialA Review: The Antiviral Activity of Cyclic Peptides
Chia, L. Y., Kumar, P. V., Maki, M. A. A., Ravichandran, G., & Thilagar, S. (2022) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-022-10478-y · Cited by 30
Structural and functional characteristics of the SARS-CoV-2 Omicron subvariant BA.2 spike protein
Zhang, J., Tang, W., Gao, H., Lavine, C. L., Shi, W. K., Peng, H., Zhu, H., Anand, K., Kosikova, M., Kwon, H. J., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01023-6 · Cited by 30
Sachs, J. D., Abdool Karim, S., Aknin, L., Allen, J., Brosbøl, K., Cuevas Barron, G., Daszak, P., Fernanda Espinosa, M., Gaspar, V., Gaviria, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00388-3 · Cited by 30
Evaluation of two RT-PCR screening assays for identifying SARS-CoV-2 variants
Migueres, M., Lhomme, S., Trémeaux, P., Dimeglio, C., Ranger, N., Latour, J., Dubois, M., Nicot, F., Miédougé, M., Mansuy, J., et al. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104969 · Cited by 30
Clinical challenges of SARS‑CoV‑2 variants (Review)
Cojocaru, C., Cojocaru, E., Turcanu, A., & Zaharia, D. C. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11343 · Cited by 30
“5 times that of the original strain (9).”
BackgroundCOVID-19 in Pakistan: A national analysis of five pandemic waves
Ahmad, T., Abdullah, M., Mueed, A., Sultan, F., Khan, A., & Khan, A. A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281326 · Cited by 32
Zhao, X., Qiu, T., Huang, X., Mao, Q., Wang, Y., Qiao, R., Li, J., Mao, T., Wang, Y., Cun, Y., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00648-1 · Cited by 34
Geographical migration and fitness dynamics of Streptococcus pneumoniae
Belman, S., Lefrancq, N., Nzenze, S. A., Downs, S., du Plessis, M., Lo, S. W., Corso, A. C., Gagetti, P. S., Brooks, A. W., Hasanuzzaman, M., et al. (2024) · Nature · doi:10.1038/s41586-024-07626-3 · Cited by 36
“The selection rate coefficient is a direct measure of the fitness advantage of emerging variants and is one of the best indicators as to whether a strain will increase in frequency during an outbreak 70,71 .”
Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection
Ameratunga, R., Woon, S., Jordan, A., Longhurst, H. J., Leung, E. Y., Steele, R. H., Lehnert, K., Snell, R. G., & Brooks, A. E. S. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1905525 · Cited by 28
Gand, M., Vanneste, K., Thomas, I., Gucht, S. V., Capron, A., Herman, P., Roosens, N. H. C., & Keersmaecker, S. C. J. D. (2021) · Genes · doi:10.3390/genes12040565 · Cited by 29
“V1 variant [30,32]; v2: mutation in 20H/501Y.”
Nuñez, I. A., Lien, C. Z., Selvaraj, P., Stauft, C. B., Liu, S., Starost, M. F., & Wang, T. T. (2021) · mSphere · doi:10.1128/msphere.00507-21 · Cited by 31
Buchan, S. A., Tibebu, S., Daneman, N., Whelan, M., Vanniyasingam, T., Murti, M., & Brown, K. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab496 · Cited by 31
High throughput diagnostics and dynamic risk assessment of SARS-CoV-2 variants of concern
Gravagnuolo, A. M., Faqih, L., Cronshaw, C., Wynn, J., Burglin, L., Klapper, P. E., & Wigglesworth, M. J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103540 · Cited by 33
“The net effect of these S gene mutations is thought to improve the ability of the virus to attach to the ACE2 cellular receptor, facilitating the infection of epithelial cells leading to the production of virus with greater transmissibility [20,21].”
Antony, P., & Vijayan, R. (2021) · Biomolecules · doi:10.3390/biom11081244 · Cited by 32
“Epidemiological studies indicated that this variant has up to 80% higher transmissibility and was associated with an increased risk of death when compared to previously reported variants [7].”
ResultSARS-CoV-2 viral RNA levels are not 'viral load'
Michalakis, Y., Sofonea, M. T., Alizon, S., & Bravo, I. G. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.08.008 · Cited by 28
Auth, J., Fröba, M., Große, M., Rauch, P., Ruétalo, N., Schindler, M., Morokutti-Kurz, M., Graf, P., Dolischka, A., Prieschl‐Grassauer, E., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910205 · Cited by 30
Rosenke, K., Feldmann, F., Okumura, A., Hansen, F., Tang-Huau, T.-L., Meade-White, K. D., Kaza, B., Callison, J. A., Lewis, M. C., Smith, B. J., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1997074 · Cited by 26
“7 (Alpha) VOC, a variant that emerged in the UK in September of 2020 and then quickly spread throughout the world [5, 7], with a contemporary D614G progenitor variant, in terms of virus replication, shedding and disease severity.”
Inferring variant-specific effective reproduction numbers from combined case and sequencing data
Figgins, M. D., & Bedford, T. (2026) · eLife · doi:10.7554/elife.104802.2 · Cited by 25
Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern
Wagner, T. R., Schnepf, D., Beer, J., Klingel, K., Ruetalo, N., Kaiser, P. D., Junker, D., Sauter, M., Traenkle, B., Frecot, D. I., et al. (2021) · EMBO Reports · doi:10.15252/embr.202153865 · Cited by 29
Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021
Stefanelli, P., Trentini, F., Dirani, G., Marziano, V., Mammone, A., Poletti, P., Grané, C. M., Manica, M., Manso, M. D., Andrianou, X. D., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.5.2100429 · Cited by 34
Self-citationGoyal, A., Reeves, D. B., & Schiffer, J. T. (2022) · Journal of The Royal Society Interface · doi:10.1098/rsif.2021.0811 · Cited by 36
“Moreover, increased transmissibility for novel variants was demonstrated by modelling and in vitro experiments showing enhanced binding to the ACE2 receptor in respiratory cell lines [1,5].”
BackgroundInfluentialLu, L., Chen, L., Zhang, R., Tsang, O. T., Chan, J. M., Tam, A. R., Leung, W.-S., Chik, T. S., Lau, D. P.-L., Choi, C. Y.-C., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103986 · Cited by 31
Basheer, A., & Zahoor, I. (2021) · Microorganisms · doi:10.3390/microorganisms9122609 · Cited by 30
“and death rates compared with other variants of SARS-CoV-2 [12, 39, 40].”
ResultEstimation of the basic reproduction number of Alpha and Delta variants of COVID-19 pandemic in Iran
Sheikhi, F., Yousefian, N., Tehranipoor, P., & Kowsari, Z. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265489 · Cited by 29
Su, W., Choy, K. T., Gu, H., Sia, S. F., Cheng, K. M., Nizami, S. I. N., Krishnan, P., Ng, Y. M., Chang, L. D. J., Liu, Y., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac276 · Cited by 27
“1093/infdis/jiac276 Since the first report of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in December 2019, the ongoing coronavirus disease 2019 (COVID-19) pandemic has been sustained by the emergence of multiple variants of concern (VOC) that differ in their capacity to spread [1, 2], cause severe di…”
BackgroundMyall, A., Price, J. R., Peach, R. L., Abbas, M., Mookerjee, S., Zhu, N., Ahmad, I., Ming, D. K. Y., Ramzan, F., Teixeira, D., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00093-0 · Cited by 34
ELF5 is a potential respiratory epithelial cell-specific risk gene for severe COVID-19
Pietzner, M., Chua, R. L., Wheeler, E., Jechow, K., Willett, J., Radbruch, H., Trump, S., Heidecker, B., Zeberg, H., Heppner, F. L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31999-6 · Cited by 33
CD8+ T-cell immune escape by SARS-CoV-2 variants of concern
Kombe, A. J. K., Biteghe, F. A. N., Ndoutoume, Z. N., & Jin, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.962079 · Cited by 30
Chen, D. W., Turcinovic, J., Feng, S., Kenney, D., Chin, C. V., Choudhary, M. C., Conway, H. L., Semaan, M., Close, B. J., Tavares, A. H., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106634 · Cited by 33
Mushebenge, A. G.-A., Ugbaja, S. C., Mbatha, N. A., Khan, R. B., & Kumalo, H. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115518 · Cited by 32
“The reliance on computer models, which are only as reliable as the underlying assumptions and data used to generate them, is a fundamental constraint [116,117].”
BackgroundGenomic reconstruction of the SARS-CoV-2 epidemic in EnglandPreprint
Vöhringer, H. S., Sanderson, T., Sinnott, M., et al. (2021) · medRxiv · doi:10.1101/2021.05.22.21257633 · Cited by 29
“…was first observed in Kent in September 2020 (Rambaut, Loman, et al., 2020), which has since swept through the United Kingdom and large parts of the world due to a transmissibility elevated by approximately 70% (N. G. Davies et al., 2021; O’Toole, Hill, et al., 2021; Volz, Mishra, et al., 2021).”
BackgroundMethodInfluentialSelf-citationKhan, R. U., Almakdi, S., Alshehri, M. S., Kumar, R., Ali, I., Hussain, S. M., Haq, A. U., Khan, I. U., Ullah, A., & Uddin, M. I. (2022) · Diagnostics · doi:10.3390/diagnostics12102539 · Cited by 29
Structural understanding of SARS-CoV-2 virus entry to host cells
Le, K. P. U., Kannappan, S., Kim, T., Lee, J. H., Lee, H.-R., & Kim, K. K. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1288686 · Cited by 40
“The Spike protein of the Alpha variant has a total of ten mutations, of which there are seven missense mutations (N501Y, A570D, P681H, D614G, T716I, S982A, and D1118H) and three deletions in residues H69, V70, and Y144 (Figure 1B) (Davies et al., 2021).”
BackgroundHasan, M., Ashik, A. I., Chowdhury, M. B., Tasnim, A. T., Nishat, Z. S., Hossain, T., & Ahmed, S. (2021) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2021.100569 · Cited by 31
“Their efforts are being challenged by the frequent mutation of the virus that has resulted in variants with higher transmission rates [5].”
Roquebert, B., Trombert‐Paolantoni, S., Haïm‐Boukobza, S., Lecorché, E., Verdurme, L., Foulongne, V., Sofonea, M. T., & Alizon, S. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.23.2100447 · Cited by 28
“…B.1.1.7, nextstrain clade 20I/501Y.V1, and GISAID clade/lineage GRY, is currently causing the majority of infections in Europe and North America [2], whereas, the second, VOC β (Pango lineage: B.1.351; nextstrain clade: 20H/501Y.V2; GISAID clade/lineage: GH/501Y.V2) is the most common variant…”
InfluentialWilliams, G. H., Llewelyn, A., Brandão, R. A. R., Chowdhary, K., Hardisty, K.-M., & Loddo, M. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101021 · Cited by 28
Sampson, A., Heeney, J. L., Cantoni, D. M., Ferrari, M., Sans, M. S., George, C. L., Genova, C. D., Neto, M. M., Einhauser, S., Asbach, B., et al. (2021) · Viruses · doi:10.3390/v13081579 · Cited by 29
Decomposing the sources of SARS-CoV-2 fitness variation in the United States
Kepler, L. M., Hamins-Puértolas, M., & Rasmussen, D. A. (2021) · Virus Evolution · doi:10.1093/ve/veab073 · Cited by 29
Schreiber, S., Faude, O., Gärtner, B. C., Meyer, T., & Egger, F. (2021) · British Journal of Sports Medicine · doi:10.1136/bjsports-2021-104441 · Cited by 31
Edwards, L., Fowlkes, A., Wesley, M. G., Kuntz, J. L., Odean, M. J., Caban-Martinez, A. J., Dunnigan, K., Phillips, A. L., Grant, L., Herring, M. K., et al. (2021) · JMIR Research Protocols · doi:10.2196/31574 · Cited by 29
“Moreover, emerging variants of SARS-CoV-2 are causing concern and have been associated with an increase in the incidence of infection and may have implications for COVID-19 vaccine effectiveness [6-8].”
Showers, W. M., Leach, S. M., Kechris, K. J., & Strong, M. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.105153 · Cited by 37
Liang, Y., Zou, L., Lin, H., Li, B., Zhao, J., Wang, H., Sun, J., Chen, J., Mo, Y., Yang, X., et al. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00643 · Cited by 28
de Souza, A. S., Amorim, V. M. D. F., Guardia, G. D. A., dos Santos, F. F., Ulrich, H., Galante, P. A. F., de Souza, R. F., & Guzzo, C. R. (2022) · Viruses · doi:10.3390/v14040827 · Cited by 30
Drug repurposing for the treatment of COVID-19
Kato, Y., Nishiyama, K., Nishimura, A., Noda, T., Okabe, K., Kusakabe, T., Kanda, Y., & Nishida, M. (2022) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2022.04.007 · Cited by 35
Ali, A. M., Tofiq, A. M., Rostam, H. M., Ali, K. M., & Tawfeeq, H. M. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28098 · Cited by 27
“7 than in pre‐ existing variants.(17) Since its emergence in December 2019, the SARS‐CoV‐2 virus has infected more than 535 million people and led to at least 6 million deaths globally.”
BackgroundChallenges of vaccination and herd immunity in COVID‐19 and management strategies
She, J., Hou, D., Chen, C., Bi, J., & Song, Y. (2022) · The Clinical Respiratory Journal · doi:10.1111/crj.13543 · Cited by 31
“SARS-CoV-2 alpha variant was highly transmissible.(11) The alpha variant included 17 mutations in viral genome.”
BackgroundGenomic epidemiology of SARS- CoV-2 Omicron variants in the Republic of Korea
Lee, D. W., Kim, J., Park, A. K., Kim, D.-W., Kim, J., Lim, N., Lee, H., Kim, I., Kim, J.-A., Lee, C. Y., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-26803-w · Cited by 29
Emergence and spread of two SARS-CoV-2 variants of interest in Nigeria
Olawoye, I. B., Oluniyi, P. E., Oguzie, J. U., Uwanibe, J. N., Kayode, A. T., Olumade, T. J., Ajogbasile, F. V., Parker, E., Eromon, P., Abechi, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36449-5 · Cited by 31
Inferring risks of coronavirus transmission from community household data
House, T., Riley, H., Pellis, L., Pouwels, K. B., Bacon, S., Eidukas, A., Jahanshahi, K., Eggo, R. M., & Walker, A. S. (2022) · Statistical Methods in Medical Research · doi:10.1177/09622802211055853 · Cited by 30
“There is evidence for both increased transmissibility of this variant, and increased mortality amongst infected cases (Davies et al., 2021; Challen et al., 2021; Grint et al., 2021), although conditional on hospitalisation outcomes may not be worse (Frampton et al., 2021).”
BackgroundSelf-citationPM2.5 as a major predictor of COVID-19 basic reproduction number in the USA
Milicevic, O. S., Salom, I., Rodic, A., Marković, S. S., Tumbas, M., Zigic, D., Djordjevic, M., & Djordjević, M. (2021) · Environmental Research · doi:10.1016/j.envres.2021.111526 · Cited by 28
“This can e.g. be compared with R 0 / R 0 of up to 90% for the Alpha strain (Davies et al., 2021) so that estimated changes due to pollution variation are smaller but still substantial.”
BackgroundInfluentialDutta, T., Baildya, N., Khan, A. A., & Ghosh, N. N. (2021) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-021-00309-3 · Cited by 27
Lind, A., Barlinn, R., Landaas, E. T., Andresen, L. L., Jakobsen, K., Fladeby, C., Nilsen, M., Bjørnstad, P. M., Sundaram, A. Y. M., Ribarska, T., et al. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104906 · Cited by 30
Transmission of Infections during Cardiopulmonary Resuscitation
Fragkou, P. C., Dimopoulou, D., Latsios, G., Koudounis, P., Synetos, A. G., Dimopoulou, A., Tsioufis, K. P., Papaevangelou, V., & Tsiodras, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00018-21 · Cited by 26
Meyer, M., Holfter, A., Ruebsteck, E., Gruell, H., Dewald, F., Koerner, R. W., Klein, F., Lehmann, C., Huenseler, C., & Weber, L. T. (2021) · Viruses · doi:10.3390/v13081600 · Cited by 26
Xia, F., Yang, X., Cheke, R., & Xiao, Y. (2021) · Infectious Disease Modelling · doi:10.1016/j.idm.2021.08.001 · Cited by 25
“Here we chose R o 0 ¼ 2 : 5, R o 0 ¼ 3 : 5, and R a 0 = R o 0 being in the interval of [1.4, 1.9] (Davies et al., 2021) as the basis for estimating the basic reproduction number of the Delta variant.”
InfluentialShooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
Günl, F., Mecate-Zambrano, A., Rehländer, S., Hinse, S., Ludwig, S., & Brunotte, L. (2021) · Vaccines · doi:10.3390/vaccines9101052 · Cited by 27
Genetic drift in the genome of SARS COV‐2 and its global health concern
Bano, I., Sharif, M., & Alam, S. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27337 · Cited by 28
Surveillance of SARS-CoV-2 lineage B.1.1.7 in Slovakia using a novel, multiplexed RT-qPCR assay
Boršová, K., Paul, E. D., Kováčová, V., Radvánszka, M., Hajdu, R., Čabanová, V., Slavíková, M., Ličková, M., Lukáčiková, Ľ., Belák, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99661-7 · Cited by 29
Modeling the onset of symptoms of COVID-19: Effects of SARS-CoV-2 variant
Larsen, J., Martin, M. R., Martin, J. D., Hicks, J. B., & Kühn, P. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009629 · Cited by 31
Li, L., Han, Z., Qin, P., Liu, W., Zhou, Y., Chen, Z.-Q., Li, K., Xie, C., Ma, Y., Wang, H., et al. (2022) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0010048 · Cited by 31
“A previous study in the United Kingdom reported that the household transmission rate associated with the Delta variant was higher than that of the Alpha variant, which was found to have a 43–90% higher reproductive number than the preexisting strains [27,28].”
BackgroundResearch progress on vaccine efficacy against SARS-CoV-2 variants of concern
Bian, L., Liu, J., Gao, F., Gao, Q., He, Q., Mao, Q., Wu, X., Xu, M., & Liang, Z. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2057161 · Cited by 31
Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review
Zhao, L., Li, S., & Zhong, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.840639 · Cited by 33
“With the continuous spread of SARS-CoV-2, various new variants have emerged, the four most notable ones being alpha, beta, gamma, and delta, which have caused recent outbreaks in many countries and regions, thus representing a major challenge in the fight to curb the pandemic (Davies et al., 2021; Faria et al., 2021;…”
BackgroundHow immunity from and interaction with seasonal coronaviruses can shape SARS-CoV-2 epidemiology
Waterlow, N. R., van Leeuwen, E., Davies, N. G., CMMID COVID-19 Working Group, Flasche, S., & Eggo, R. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2108395118 · Cited by 30
Self-citationHallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors
Rovito, R., Augello, M., Ben-Haim, A., Bono, V., Monforte, A. D., & Marchetti, G. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.912336 · Cited by 35
Effective high-throughput RT-qPCR screening for SARS-CoV-2 infections in children
Dewald, F., Suárez, I., Johnen, R., Großbach, J., Morán-Tovar, R., Steger, G., Joachim, A., Horemheb-Rubio, G., Fries, M., Behr, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30664-2 · Cited by 26
Blasioli, E., Mansouri, B., Tamvada, S. S., & Hassini, E. (2023) · Operations Research Forum · doi:10.1007/s43069-023-00194-8 · Cited by 39
Kun, Á., Hubai, A. G., Král, A., Mokos, J., Mikulecz, B. Á., & Radványi, Á. (2023) · Biologia Futura · doi:10.1007/s42977-023-00159-2 · Cited by 31
An overview of SARS-CoV-2 transmission and engineering strategies to mitigate risk
Leo, B. F., Lin, C. Y., Markandan, K., Saw, L. H., Nadzir, M. S. M., Govindaraju, K., Shariffuddin, I. I., Sankaran, R., Tiong, Y. W., Pakalapati, H., et al. (2023) · Journal of Building Engineering · doi:10.1016/j.jobe.2023.106737 · Cited by 37
Kiem, C. T., & Bedford, T. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305299121 · Cited by 22
“In the early stages of their spread, variants of concerns (VOCs) such as Alpha, Delta or Omicron have been associated with initially short doubling times (35–38), corresponding to reproduction numbers above the threshold of 1/𝑝 .”
BackgroundNeutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsPreprint
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-400230/v1 · Cited by 27
The first three waves of the Covid-19 pandemic hint at a limited genetic repertoire for SARS-CoV-2
Wassenaar, T. M., Wanchai, V., Buzard, G. S., & Ussery, D. W. (2022) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuac003 · Cited by 32
“The rapid spread of a variant carrying the S:A222V mutation in Europe mid-2020 (Hodcroft et al. 2021) was mainly caused by members of Janus.”
BackgroundInfluentialSARS-CoV-2: pathogenesis, therapeutics, variants, and vaccines
Li, X., Mi, Z., Liu, Z., & Rong, P. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1334152 · Cited by 42
“SARS-CoV-2 has the ability to produce significant genomic changes (Davies et al., 2021; Harvey et al., 2021).”
BackgroundComparative evaluation of behavioral epidemic models using COVID-19 data
Gozzi, N., Perra, N., & Vespignani, A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2421993122 · Cited by 41
Bosetti, P., Kiem, C. T., Andronico, A., Vittoria Colizza, A., Yazdanpanah, Y., Fontanet, A. L., Benamouzig, D., & Cauchemez, S. (2022) · BMC Medicine · doi:10.1186/s12916-022-02235-1 · Cited by 24
KORNITZER, J. M., Johnson, J., Yang, M., Pecor, K. W., Cohen, N., Jiang, C., & Ming, X. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18168269 · Cited by 33
“7) originating from the United Kingdom, have been found to be more infectious and deadly in adults, limited research exists in the clinical presentation and outcomes of different SARS-CoV-2 variants in children [82].”
BackgroundRattanapisit, K., Bulaon, C. J. I., Khorattanakulchai, N., Shanmugaraj, B., Wangkanont, K., & Phoolcharoen, W. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253574 · Cited by 26
Lee, B. U. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18189804 · Cited by 28
Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants
Bayarri‐Olmos, R., Jarlhelt, I., Johnsen, L. B., Hansen, C. B., Helgstrand, C., Bjelke, J. R., Matthiesen, F., Nielsen, S. D., Iversen, K. K., Ostrowski, S. R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.757197 · Cited by 28
Murugan, C., Ramamoorthy, S., Kuppuswamy, G. P., Murugan, R. K., Sivalingam, Y., & Sundaramurthy, A. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.10.144 · Cited by 31
Rapid test to assess the escape of SARS-CoV-2 variants of concern
Heggestad, J. T., Britton, R. J., Kinnamon, D., Wall, S. A., Joh, D. Y., Hucknall, A., Olson, L. B., Anderson, J. G., Mazur, A., Wolfe, C. R., et al. (2021) · Science Advances · doi:10.1126/sciadv.abl7682 · Cited by 26
Takamatsu, Y., Imai, M., Maeda, K., Nakajima, N., Higashi‐Kuwata, N., Iwatsuki‐Horimoto, K., Ito, M., Kiso, M., Maemura, T., Takeda, Y., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01551-21 · Cited by 25
Markt, R., Endler, L., Amman, F., Schedl, A., Penz, T., Büchel-Marxer, M., Grünbacher, D., Mayr, M., Peer, E., Pedrazzini, M., et al. (2021) · Journal of Water and Health · doi:10.2166/wh.2021.180 · Cited by 28
Dynamics of SARS-CoV-2 Alpha (B.1.1.7) variant spread: The wastewater surveillance approach
Carcereny, A., García-Pedemonte, D., Martínez-Velázquez, A., Quer, J., García‐Cehic, D., Gregori, J., Antón, A., Andrés, C., Pumarola, T., Chacón-Villanueva, C., et al. (2022) · Environmental Research · doi:10.1016/j.envres.2022.112720 · Cited by 24
Lafon, E., Jäger, M., Bauer, A., Reindl, M., Bellmann‐Weiler, R., Wilflingseder, D., Lass‐Flörl, C., & Posch, W. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.01.013 · Cited by 34
“7 or the Alpha variant, with a N501Y mutation, was found to be more infectious and transmissible, but whether disease severity is affected remains unclear.(11,12) Currently, the phylogenetic landscape has changed tremendously with the emergence of B.”
Fisman, D. N., & Tuite, A. R. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac174 · Cited by 24
“4 Introduction 50 51 Emerging SARS-CoV-2 variants of concern (VOC) have displayed increased infectivity as well 52 as increased virulence relative to strains circulating early in the pandemic (1-7).”
Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display
Tanaka, S., Olson, C. A., Barnes, C. O., Higashide, W., Gonzalez, M. R., Taft, J. D., Richardson, A., Martín-Fernández, M., Bogunovic, D., Gnanapragasam, P. N. P., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110348 · Cited by 20
“Despite the rapid development and success of vaccines and antibody therapies, ongoing SARS-CoV-2 antigenic drift has resulted in the emergence of variants that pose new threats (Davies et al., 2021; Plante et al., 2021; Yurkovetskiy et al., 2020).”
Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2
Lee, R. K., Li, T., Chang, S., Chao, T., Kuo, C.-H., Pan, M. Y.-C., Chiou, Y.-T., Liao, K.-J., Yang, Y., Wu, Y., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23074050 · Cited by 28
Molecular Beacons Allow Specific RT-LAMP Detection of B.1.1.7 Variant SARS-CoV-2
Sherrill-Mix, S. A., Duyne, G. D. V., & Bushman, F. D. (2021) · Journal of Biomolecular Techniques JBT · doi:10.7171/jbt.21-3203-004 · Cited by 28
Panovska‐Griffiths, J., Swallow, B., Hinch, R., Cohen, J. A., Rosenfeld, K., Stuart, R. M., Ferretti, L., Lauro, F. D., Wymant, C., Izzo, A. S., et al. (2022) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2021.0315 · Cited by 29
Self-citationDaou, M., Kannout, H., Khalili, M., Almarei, M., Alhashami, M., Alhalwachi, Z., Alshamsi, F. Y., Bataineh, M. T. A., Kayasseh, M. A., AlKhajeh, A. S., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274961 · Cited by 28
“These mutations have been found in some cases to trigger higher transmission and virulence [38], and potential resistance to natural or acquired immunity [39, 40], and this can be linked to a higher replication rate of the virus.”
BackgroundAntigenic evolution of SARS-CoV-2 in immunocompromised hosts
Smith, C. A., & Ashby, B. (2022) · Evolution Medicine and Public Health · doi:10.1093/emph/eoac037 · Cited by 28
“7) variant (relative to the wild type) [1], and by the Delta (B.”
BackgroundLyu, S., Chen, Q., McIntyre, A., & Lee, C. (2023) · Healthcare · doi:10.3390/healthcare11131848 · Cited by 35
“These three variants were 43%–90% [49], 25%–60%, and 38%–60% [50,51] more transmissible than the original strain, and the hazard of death associated with them was 61%–67% [52,53], 26%–74% [54], and 24%–54% [55] higher than with the original strain, respectively.”
BackgroundCohen, J. A., Stuart, R. M., Rosenfeld, K., Lyons, H. M., White, M. T., Kerr, C. C., Klein, D. J., & Famulare, M. (2021) · medRxiv · doi:10.1101/2021.05.31.21258018 · Cited by 22
Song, R., Li, D., Hao, X., Lyu, Q., Ma, Q., Chen, X., & Qiao, L. (2024) · Open Research (University of Surrey) · doi:10.1002/viw.20240015 · Cited by 27
Inagaki, H., Saito, A., Kaneko, C., Sugiyama, H., Okabayashi, T., & Fujimoto, S. (2021) · Pathogens · doi:10.3390/pathogens10060754 · Cited by 26
Up State of the SARS-COV-2 Spike Homotrimer Favors an Increased Virulence for New Variants
Giron, C. C., Laaksonen, A., & da Silva, F. L. B. (2021) · Frontiers in Medical Technology · doi:10.3389/fmedt.2021.694347 · Cited by 28
Metadata
- Authors
- Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., Wenseleers, T., Gimma, A., Waites, W., Wong, K. L. M., van Zandvoort, K., Silverman, J. D., CMMID COVID-19 Working Group, COVID-19 Genomics UK (COG-UK) Consortium, Diaz-Ordaz, K., Keogh, R., Eggo, R. M., Funk, S., Jit, M., Atkins, K. E., & Edmunds, W. J.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- Selva Analytics LLC, Bozeman, MT, USA.
- KU Leuven (BE)
- Pennsylvania State University (US)
- Centre for Statistical Methodology and Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
- Corresponding author
- Davies, Nicholas G.
- ORCID
- Davies, Nicholas G.
- Abbott, Sam
- Barnard, Rosanna C.
- Jarvis, Christopher I.
- Kucharski, Adam J.
- Munday, James D.
- Pearson, Carl A. B.
- Russell, Timothy W.
- Tully, Damien C.
- Washburne, Alex D.
- Wenseleers, Tom
- Gimma, Amy
- Waites, William
- Wong, Kerry L. M.
- van Zandvoort, Kevin
- Silverman, Justin D.
- Diaz-Ordaz, Karla
- Keogh, Ruth
- Eggo, Rosalind M.
- Funk, Sebastian
- Jit, Mark
- Atkins, Katherine E.
- Edmunds, W. John
- Venue
- Science
- Published
- 2021-04-09
- Volume
- 372
- Issue
- 6538
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8128288
- OpenAlex
- W3134208712
- Semantic Scholar
- 34e9a0b4e42a4971a3a124c818045741c734fb9e
- Cited by
- 2,581
- References
- 58
- Citations by year
- 2026: 74 · 2025: 102 · 2024: 199 · 2023: 330 · 2022: 840 · 2021: 1028
- FWCI
- 215.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (submittedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion, cc-by)
- Northumbria Research Link (Northumbria University) (acceptedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- University of Kentucky
- Universität Bern
- Universitätsspital Basel
- National Institute for Health Research (NIHR200908)
- European Commission (101003688)
- CANDU Owners Group
- Hôpitaux Universitaires de Genève
- Eidgenössische Technische Hochschule Zürich
- Université de Sfax
- UKRI Research England (NA)
- National Institute for Health Research Health Protection Research Unit in Immunisation (NIHR200929)
- United Kingdom Medical Research Council (MC_PC_19065)
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Applied Mathematics › Mathematical and Theoretical Epidemiology and Ecology Models
- Keywords
- SARS-CoV-2, B.1.1.7 variant, reproduction number, SARS-CoV-2 transmission, epidemic forecasting, COVID-19 containment measures, vaccine rollout, school closures, England
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Communicable Disease Control, England, Europe, Female, Humans, Infant, Male, Middle Aged, Models, Theoretical, Mutation, Severity of Illness Index, Socioeconomic Factors, United States, Viral Load, Basic Reproduction Number, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.